{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"30.520","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"2,432,426,412","primaryexch":"香港交易所","ric":"1530.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"B","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.8625,"inline_upper_strike_price":"","sedol":"BY9D3L9","am":"1.17","iv":"","ew_strike":"","as":"29.080","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"29.060","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"5.470","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"婁競","underlying_ric":"1530.HK","hi52":"36.800","issuer_name":"三生製藥","h_share_flag":false,"ew_sub_per_from":"","div_yield":"0.86","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"29.000","mkt_cap":"70.73","f_aum_hkd":null,"ew_sub_per_to":"","ls":"29.080","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-1.640","aum":"","issued_shares_class_B":null,"vo":"39.78","secondary_listing_flag":false,"listing_date":"2015年6月11日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"三生製藥","nm_s":"三生製藥","sym":"1530","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"3SBio Inc是一家主要從事生物製藥產品的開發、生產、市場推廣及銷售的投資控股公司。該公司的主要產品包括特比澳、益比奧、益賽普、賽普汀等生物藥物以及蔓迪、麗美治等小分子藥物。該公司還從事為客戶提供多種生物藥的研發生產以及治療技術平臺服務的合同開發與生產運營（CDMO）業務。該公司的產品主要應用於血小板減少癥（CIT）、慢性腎病（CKD）引起的貧血癥、治療化療引起的貧血癥（CIA）、強直性脊柱炎（AS）及銀屑病等。該公司主要在中國國內和海外市場開展業務。","op":"30.100","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>希慎道33號<br/>利園一期<br/>19樓1918室","pc":"-5.34","days_to_expiry":null,"underlying_code":null,"pe":"31.84","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"30.720","isin":"KYG8875G1029","moneyness":""}},"qid":"1759073989637"}
